Inhibition of the Biologic Activity of Tumor Necrosis Factor Maintains Vascular Endothelial Cell Function during Hyperdynamic Sepsis

Journal of Trauma - Injury, Infection and Critical Care

Volumn 40, Issue 5, 1996, Pages 694-700

  Wang, Ping ^a,b,c   Wood, Thomas J ^a   Zhou, Mian ^a,c   Ba, Zheng F ^a,c   Chaudry, Irshad H ^a,b,c,d  

^a MICHIGAN STATE UNIVERSITY   (United States)

^b MICHIGAN STATE UNIVERSITY   (United States)

^c BROWN UNIVERSITY   (United States)

^d RHODE ISLAND HOSPITAL   (United States)

Author keywords

Acetylcholine; Aorta; Cecal ligation and puncture; Endothelium derived nitric oxide; Nitroglycerine; Norepinephrine; TNF binding proteins

Indexed keywords

ACETYLCHOLINE; GLYCERYL TRINITRATE; TUMOR NECROSIS FACTOR;

ANIMAL EXPERIMENT; ARTICLE; CELL PROTECTION; DOSE RESPONSE; DRUG EFFECT; ENDOTHELIUM CELL; IMMUNOREGULATION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SEPSIS; VASCULAR ENDOTHELIUM; VASODILATATION;

ACETYLCHOLINE; ANALYSIS OF VARIANCE; ANIMALS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; ENDOTHELIUM, VASCULAR; MALE; NITROGLYCERIN; POLYETHYLENE GLYCOLS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, TUMOR NECROSIS FACTOR; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; SEPSIS; TUMOR NECROSIS FACTOR DECOY RECEPTORS; TUMOR NECROSIS FACTOR-ALPHA; VASODILATOR AGENTS;

EID: 0029886397     PISSN: 00225282     EISSN: 15298809     Source Type: Journal    
DOI: 10.1097/00005373-199605000-00003     Document Type: Article

References (49)

1. Parker MM: Cardiac dysfunction in human septic shock. Ann Intern Med 113:227, 1990
2. Baue AE: Multiple Organ Failure. In Baue AE (ed): Multiple Organ Failure: Patient Care and Prevention. St. Louis, Mosby Year Book, 1990, pp 421-470
3. Deitch EA: Multiple Organ Failure: Pathophysiology and potential future therapy. Ann Surg 216:117, 1992
4. Bone RC: Sepsis and its complications: The clinical problem. Crit Care Med 22:S8, 1994
5. Callery MP, Kamei T, Mangino MJ, et al: Organ interactions in sepsis: Host defense and the hepatic-pulmonary macrophage axis. Arch Surg 126:28, 1991
6. Schlag G, Redl H, Davies J, et al: Anti-tumor necrosis factor antibody treatment of recurrent bacteremia in a baboon model. Shock 2:10, 1994
7. Van Zee KJ, Kohno T, Fischer E, et al: Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor a in vitro and in vivo. Proc Natl Acad Sci USA 89:4845, 1992
8. Drost AC, Burleson DG, Cioffi WG, et al: Plasma cytokines after thermal injury and their relationship to infection. Ann Surg 218:74, 1993
9. Ogura H, Cioffi WG, Offner PJ, et al: Effect of inhaled nitric oxide on pulmonary function after sepsis in a swine model. Surgery 116:313, 1994
10. Lang CH, Bagby GJ, Ferguson JL, et al: Cardiac output and redistribution of organ blood flow in hypermetabolic sepsis. Am J Physiol 246:R331, 1984
11. Dahn MS, Lange MP, Wilson RF, et al: Hepatic blood flow and splanchnic oxygen consumption measurements in clinical sepsis. Surgery 107:295, 1990
12. Wang P, Ba ZF, Chaudry IH: Hepatic extraction of indocyanine green is depressed early in sepsis despite increased hepatic blood flow and cardiac output. Arch Surg 126:219, 1991
13. Wang P, Zhou M, Rana MW, et al: Differential alterations in microvascular perfusion in various organs during early and late sepsis. Am J Physiol 263:G38, 1992
14. Wang P, Ba ZF, Chaudry IH: Nitric oxide: To block or enhance its production during sepsis? Arch Surg 129:1137, 1994
15. Wang P, Ba ZF, Chaudry IH: Endothelium-dependent relaxation is depressed at the macro- and microcirculatory levels during sepsis. Am J Physiol 269:R988, 1995
16. Ertel W, Morrison MH, Wang P, et al: The complex pattern of cytokines in sepsis: Association between prostaglandins, cachectin and interleukins. Ann Surg 214:141, 1991
17. Wang P, Ba ZF, Chaudry IH: Administration of tumor necrosis factor-α in vivo depresses endothelium-dependent relaxation. Am J Physiol 266:H2535, 1994
18. Wang P, Ayala A, Ba ZF, et al: Tumor necrosis factor-α produces hepatocellular dysfunction despite normal cardiac output and hepatic microcirculation. Am J Physiol 265:G126, 1993
19. Chaudry IH, Wichterman KA, Baue AE: Effect of sepsis on tissue adenine nucleotide levels. Surgery 85:205, 1979
20. Wang P, Ba ZF, Chaudry IH: Increase in hepatic blood flow during early sepsis is due to increased portal blood flow. Am J Physiol 261:R1507, 1991
21. Wang P, Ba ZF, Chaudry IH: Endothelial cell dysfunction occurs very early following trauma-hemorrhage and persists despite fluid resuscitation. Am J Physiol 265:H973, 1993
22. Pinsky MR, Vincent JL, Deviere J, et al: Serum cytokine levels in human septic shock: Relation to multiple-system organ failure and mortality. Chest 103:565, 1993
23. Strieter RM, Kunkel SL, Bone RC: Role of tumor necrosis factor-α in disease states and inflammation. Crit Care Med 21:S447, 1993
24. Marks JD, Marks CB, Luce JM, et al: Plasma tumor necrosis factor in patients with septic shock. Am Rev Respir Dis 141:94, 1990
25. Ayala A, Herdon CD, Lehman DL, et al: The induction of accelerated thymic programmed cell death during polymicrobial sepsis: Control by corticosteroids but not tumor necrosis factor. Shock 3:259, 1995
26. Damas P, Reuter A, Gysen P, et al: Tumor necrosis factor and interleukin-1 serum levels during severe sepsis in humans. Crit Care Med 17:975, 1989
27. Rogy MA, Coyle SM, Oldenburg HS, et al: Persistently elevated soluble tumor necrosis factor and interleukin-1 receptor antagonist levels in critically ill patients. J Am Coll Surg 178:132, 1994
28. Spinas GA, Keller U, Brockhaus M: Release of soluble receptors for tumor necrosis factor (TNF) in relation to circulating TNF during experimental endotoxemia. J Clin Invest 90:533, 1992
29. Bargetzi MJ, Lantz M, Smith CG, et al: Interleukin-1 beta induces interleukin-1 receptor antagonist and tumor necrosis factor binding protein in humans. Cancer Res 53:4010, 1993
30. Bertini R, Delgado R, Faggioni R, et al: Urinary TNF-binding protein (TNF soluble receptor) protects mice against the lethal effect of TNF and endotoxic shock. Eur Cytokine Netw 4:39, 1993
31. Ashkenazi A, Marsters SA, Capon DJ, et al: Protection against endotoxic shock by a tumor necrosis factor receptor immunoadhesin. Proc Natl Acad Sci USA 88:10535, 1991
32. Evans TJ, Moyes D, Carpenter A, et al: Protective effect of 55- but not 75-kD soluble tumor necrosis factor receptor-immunoglobulin G fusion proteins in an animal model of gram-negative sepsis. J Exp Med 180:2173, 1994
33. Lesslauer W, Tabuchi H, Gentz R, et al: Recombinant soluble tumor necrosis factor receptor proteins protect mice from lipopolysaccharide-induced lethality. Eur J Immunol 21:2883, 1991
34. Ythier A, Gascon MP, Juillard P, et al: Protective effect of natural TNF-binding protein on human TNF-induced toxicity in mice. Cytokine 5:459, 1993
35. Kapadia S, Torre-Amione G, Yokoyama T, et al: Soluble TNF binding proteins modulate the negative inotropic properties of TNF-alpha in vitro. Am J Physiol 268:H517, 1995
36. Hauptman JG, DeJong GK, Blasko KA, et al: Measurement of hepatocellular function, cardiac output, effective blood volume and oxygen saturation in the rat. Am J Physiol 257:R439, 1989
37. Gascon MP, Porchet HC, LeCotonnec JY, et al: Pharmacokinetics and tissue distribution of human urinary tumor necrosis factor binding protein in mice. Drug Metab Dispos 20:592, 1992
38. Russel D, Tucker K, Thompson R, et al: Synergistic protection against lethal endotoxemia by treatment with interleukin-1 receptor antagonist and tumor necrosis factor binding protein. Lymphokine Cytokine Res 12:377, 1993 (Abstract)
39. Pittner RA, Spitzer JA: Endotoxin and TNFα directly stimulate nitric oxide formation in cultured rat hepatocytes from chronically endotoxemic rats. Biochem Biophys Res Commun 185:430, 1992
40. Palmer RMJ: The discovery of nitric oxide in the vessel wall: A unifying concept in the pathogenesis of sepsis. Arch Surg 128:396, 1993
41. Evans T, Carpenter A, Kinderman H, et al: Evidence of increased nitric oxide production in patients with the sepsis syndrome. Circ Shock 41:77, 1993
42. Billiar TR: Nitric oxide: Novel biology with clinical relevance. Ann Surg 221:339, 1995
43. Young JS, Headrick JP, Berne RM: Endothelial-dependent and -independent responses in the thoracic aorta during endotoxic shock. Circ Shock 35:25, 1991
44. Myers PR, Wright TF, Tanner MA, et al: EDRF and nitric oxide production in cultured endothelial cells: Direct inhibition by E. coli endotoxin. Am J Physiol 262:H710, 1992
45. Curran RD, Billiar TR, Stuehr DJ, et al: Multiple cytokines are required to induce hepatocyte nitric oxide production and inhibit total protein synthesis. Ann Surg 212:462, 1990
46. Shepherd JT, Katusic ZS: Endothelium-derived vasoactive factors: I. Endothelium-dependent relaxation. Hypertension 18:111-76, 1991
47. Aoki N, Johnson G, III, Lefer AM: Beneficial effects of two forms of NO administration in feline splanchnic artery occlusion shock. Am J Physiol 258:G275, 1990
48. Siegfried MR, Erhardt J, Rider T, et al: Cardioprotection and attenuation of endothelial dysfunction by organic nitric oxide donors in myocardial ischemia-reperfusion. J Pharmacol Exp Therapeutics 260:668, 1992
49. Gianott L, Alexander JW, Pyles T, et al: Arginine-supplemented diets improve survival in gut-derived sepsis and peritonitis by modulating bacterial clearance: The role of nitric oxide. Ann Surg 217:644, 1993